|
Title
|
Publication Date
|
Price
|
Relevance
|
|
IMS Company Profiles:Takeda
|
Dec 2011 |
£640 |
100% |
|
Takeda Pharmaceutical Co. Ltd: PharmaVitae Model
|
Jan 2009 |
£3,605 |
99% |
|
Takeda: Pipeline, Products, Performance, Potential
|
Nov 2009 |
£595 |
99% |
|
Takeda Pharmaceuticals North America, Inc.-Detailed Product Pipeline
|
Mar 2011 |
£475 |
98% |
|
Takeda Pharmaceutical Company Limited-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
98% |
Laboratoires Takeda - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
98% |
|
Takeda Pharmaceuticals North America, Inc.-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
98% |
Takeda Pharmaceutical Co., Ltd
PharmaVitae Profile
|
Oct 2010 |
£3,605 |
98% |
|
Takeda Cambridge Limited (TCB)-Deals & Alliances Report
|
Mar 2011 |
£380 |
98% |
Takeda Pharmaceutical Company - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
98% |
|
Takeda Pharmaceuticals North America, Inc.-Deals & Alliances Report
|
Mar 2011 |
£380 |
97% |
Takeda Pharmaceutical Company Limited
Strategy and SWOT Report
|
Jun 2011 |
£79 |
97% |
|
Takeda Pharmaceutical Company Limited-Deals & Alliances Report
|
Mar 2011 |
£380 |
97% |
Takeda Pharmaceuticals North America - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
97% |
|
Partnering Agreements with Takeda 2010
|
Jan 2010 |
£630 |
97% |
Millenium: The Takeda Oncology Company - Product Pipeline Review
Q4 2010
|
Dec 2010 |
£315 |
96% |
|
The Pharmaceutical Market: Japan
|
Oct 2011 |
£595 |
87% |
Nonhematologic Malignancy Global Clinical Trials Review
Q1, 2011
|
Jan 2011 |
£630 |
85% |
|
Anemia Drugs
|
Apr 2010 |
£2,500 |
84% |
|
Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets
|
Jul 2010 |
£3,065 |
83% |
|
Wound Treatments - Japan
|
Jun 2010 |
£600 |
83% |
|
Slimming Products - Japan
|
Jun 2010 |
£600 |
83% |
|
Analgesics in Japan
|
Jul 2011 |
£675 |
82% |
|
Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
|
Mar 2009 |
£1,265 |
82% |
|
Millennium Pharmaceuticals - SWOT Analysis
|
Nov 2008 |
£79 |
82% |
|
The Japanese Pharmaceutical Market 20082023
|
Oct 2008 |
£1,499 |
82% |
|
Digestive Remedies in Japan
|
Jul 2011 |
£675 |
82% |
Domain Therapeutics – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
82% |
|
DPP IV Inhibitors
|
Sep 2011 |
£2,655 |
81% |
Hypertension Global Clinical Trials Review, Q1
2011
|
Jan 2011 |
£630 |
81% |
